Nomogram predicting efficacy of collagenase clostridium histolyticum (CCH-Xiapex®) in patients with penile curvature

Peyronie’s disease (PD) has a devastating effect on patients and their partners. Several non-surgical therapies have been tried in PD. However, their efficacy remains questionable, as well- designed, placebo-controlled trials have failed to confirm favourable results. Collagenase clostridium histolyticum (CCH-Xiapex®) is the only licensed product for the treatment of PD as it has demonstrated safety and efficacy in several well designed clinical trials. The aim of our study was to evaluate the safety and efficacy of Xiapex after the first injection and to build-up a nomogram able to identify predictive factors of penile curvature improvement (−20.0 degrees).